- Home
- AGEN vs SRBK Comparison
AGEN vs SRBK Comparison
Compare AGEN & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SRBK
- Stock Information
- Founded
- AGEN 1994
- SRBK 1887
- Country
- AGEN United States
- SRBK United States
- Employees
- AGEN N/A
- SRBK N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SRBK
- Sector
- AGEN Health Care
- SRBK
- Exchange
- AGEN Nasdaq
- SRBK Nasdaq
- Market Cap
- AGEN 96.2M
- SRBK 104.5M
- IPO Year
- AGEN 2000
- SRBK N/A
- Fundamental
- Price
- AGEN $3.83
- SRBK $12.02
- Analyst Decision
- AGEN Buy
- SRBK
- Analyst Count
- AGEN 3
- SRBK 0
- Target Price
- AGEN $10.50
- SRBK N/A
- AVG Volume (30 Days)
- AGEN 399.9K
- SRBK 17.8K
- Earning Date
- AGEN 03-13-2025
- SRBK 01-01-0001
- Dividend Yield
- AGEN N/A
- SRBK N/A
- EPS Growth
- AGEN N/A
- SRBK N/A
- EPS
- AGEN N/A
- SRBK 0.11
- Revenue
- AGEN $160,427,000.00
- SRBK $30,867,000.00
- Revenue This Year
- AGEN N/A
- SRBK N/A
- Revenue Next Year
- AGEN $36.13
- SRBK N/A
- P/E Ratio
- AGEN N/A
- SRBK $105.06
- Revenue Growth
- AGEN 59.00
- SRBK 164.18
- 52 Week Low
- AGEN $2.50
- SRBK $8.94
- 52 Week High
- AGEN $19.69
- SRBK $12.76
- Technical
- Relative Strength Index (RSI)
- AGEN 65.58
- SRBK 57.34
- Support Level
- AGEN $3.08
- SRBK $11.78
- Resistance Level
- AGEN $3.29
- SRBK $11.95
- Average True Range (ATR)
- AGEN 0.27
- SRBK 0.18
- MACD
- AGEN 0.08
- SRBK -0.02
- Stochastic Oscillator
- AGEN 94.84
- SRBK 44.18
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.